Table 6.

Effect of hypertonic saline and furosemide on hemodynamic variables in a randomized, cross-over study of 24 healthy subjects

Period	Baseline	Hypertonic saline infusion	Post hypertonic saline infusion
	0–90 min	90–150 min	150–180 min	180–210 min	210–240 min	240–300 min	P (GLM within)
SBP (mmHg)
Placebo	118 ± 9	118 ± 10	117 ± 9	119 ± 10	117 ± 10	120 ± 9	0.001
Furosemide	117 ± 7	120 ± 13	114 ± 6*	111 ± 8*	113 ± 8*	116 ± 8
P (GLM between)	0.202
DBP (mmHg)
Placebo	68 ± 7	67 ± 7	64 ± 8*	67 ± 7*	66 ± 6*	67 ± 8	0.003
Furosemide	68 ± 6	69 ± 7	67 ± 8	66 ± 6*	67 ± 7*	66 ± 6*
P (GLM between)	0.740
HR (beats/min)
Placebo	62 ± 10	66 ± 11*	63 ± 11	64 ± 10*	62 ± 10	64 ± 11*	0.354
Furosemide	61 ± 8	65 ± 10*	63 ± 9*	63 ± 8*	64 ± 10*	64 ± 10*
P (GLM between)	0.875

SBP, DBP Systolic and diastolic blood pressure, HR heart rate, cSBP, cDBP central systolic and diastolic blood pressure, AI augmentation index VR vascular resistance. Blood pressure was measured every 30 min in the 90 min baseline period, once after 60 min of hypertonic infusion, and every 30 min 90 min after hypertonic saline infusion and once 150 min after cessation of hypertonic saline infusion. Data from four baseline measurements are pooled and shown as one period. Data are presented as means ± SD. Statistics are performed with a general linear model (GLM) or paired t-test. Statistically significant difference from baseline: * = p < 0.05